Merkel cell carcinoma (MCC) is a rare type of skin cancer. It usually appears as a painless, firm, and shiny red, purple, or pink nodule on the skin. MCC most commonly occurs on areas such as the head and neck region, and less frequently on the upper extremities, trunk, and lower extremities. Risk factors include sun exposure, weak immune system, fair skin, and age above 65 years. The treatment options for MCC include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy.
The Global Merkel Cell Carcinoma Market is estimated to be valued at USD 2.51 Bn in 2024 and is expected to reach USD 3.38 Bn by 2031, growing at a compound annual growth rate (CAGR) of 4.1% from 2024 to 2031.
Key Takeaways
Key players operating in the Merkel cell carcinoma treatment market are Merck & Co. Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Heralt BioPharma etc.
Increasing incidence rates of skin cancers including melanoma and non-melanoma types such as MCC are a major growth driver for the Merkel Cell Carcinoma Market. According to estimates, over 100,000 new cases of MCC are diagnosed each year worldwide.
Recent advancements in immunotherapy have expanded treatment options for advanced/metastatic stages of MCC. Drugs such as avelumab and pembrolizumab have significantly improved patient outcomes and survival rates compared to chemotherapy.
Market Trends
Combination therapies involving immunotherapy drugs along with radiation and chemotherapy are emerging as a promising treatment approach. Ongoing clinical trials are evaluating the safety and efficacy of combinations.
Adoptive cell therapy using genetically modified T cells is another innovative treatment modality being evaluated for MCC. Several early phase clinical studies indicate manageable safety profiles and encouraging response rates.
Market Opportunities
The incidence of MCC is rising worldwide owing to aging populations and increased UV ray exposure. Under-diagnosis remains a challenge in developing countries presenting major market potential.
Ongoing research into viral causes and molecular pathogenesis of MCC can uncover novel targets and therapies. Immuno-oncology combinations and personalized medicine approaches offer scope for future market growth.
Impact of COVID-19 on Merkel Cell Carcinoma Market Growth
The Covid-19 pandemic has significantly impacted the growth of the Merkel cell carcinoma market globally. During the initial phases of the pandemic, most elective surgeries and non-emergency procedures got postponed while healthcare resources were diverted to treat COVID-19 patients. This led to a decline in the number of patients diagnosed with Merkel cell carcinoma as well as those undergoing treatment procedures like chemotherapy, immunotherapy, etc. This negatively impacted the market growth in 2020.
However, as the effects of the pandemic lessened to some extent from mid-2021 due to the initiation of vaccination drives worldwide, the market started regaining lost ground. Nevertheless, the overall growth remains below pre-pandemic projections due to the residual effect of delayed diagnosis and treatment volume in 2020. Going forward, continued vaccination efforts and resumption of regular healthcare services are expected to help restore the market growth trajectory. Meanwhile, key market players are focusing on raising awareness about this rare form of skin cancer and developing advanced medications to gain lost market share in the post-pandemic period.
Geographical Regions with High Merkel Cell Carcinoma Value Concentration
The North America region accounts for the largest share of the global Merkel cell carcinoma market in terms of value. This is attributed to the high prevalence rates of the disease in the United States and Canada coupled with advanced healthcare systems that enable early diagnosis and widespread access to state-of-the-art treatment options in the region. Various awareness initiatives by government and non-profit bodies also contribute to the high growth of the North America market.
Fastest Growing Region for Merkel Cell Carcinoma Market
The Asia Pacific region is anticipated to witness the fastest growth over the forecast period owing to rapidly evolving healthcare systems, growing medical tourism industry and rising penetration of healthcare insurance especially in developing markets like India, China, South Korea and Indonesia. In addition, increasing awareness about rare cancers and improving collaboration between regional healthcare providers and global biopharma companies will further propel the APAC market during the forecast timeline.
Get More Insights On- Merkel Cell Carcinoma Market
Get This Report in Japanese Language: メルケル細胞癌市場
Get This Report in Korean Language: 메르켈 세포 암 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Russian
Romaian
Portuguese (Brazil)
Greek